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Retinal degenerative diseasesRecent studies have suggested a possible involvement of abnormal tau in some retinal degenerative diseases.
The common view in these studies is that these retinal diseases share the mechanism of tau-mediated degen-
erative diseases in brain and that information about these brain diseases may be directly applied to explain
these retinal diseases. Here we collectively examine this view by revealing three basic characteristics of tau
in the rod outer segment (ROS) of bovine retinal photoreceptors, i.e., its isoforms, its phosphorylation
mode and its interaction with microtubules, and by comparing them with those of brain tau. We ﬁnd that
ROS contains at least four isoforms: three are identical to those in brain and one is unique in ROS. All ROS
isoforms, like brain isoforms, are modiﬁed with multiple phosphate molecules; however, ROS isoforms
show their own speciﬁc phosphorylation pattern, and these phosphorylation patterns appear not to be iden-
tical to those of brain tau. Interestingly, some ROS isoforms, under the normal conditions, are phosphorylated
at the sites identical to those in Alzheimer's patient isoforms. Surprisingly, a large portion of ROS isoforms
tightly associates with a membranous component(s) other than microtubules, and this association is inde-
pendent of their phosphorylation states. These observations strongly suggest that tau plays various roles in
ROS and that some of these functions may not be comparable to those of brain tau. We believe that knowl-
edge about tau in the entire retinal network and/or its individual cells are also essential for elucidation of
tau-mediated retinal diseases, if any.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Microtubules (MTs), a major component of the cytoskeleton, partic-
ipate in numerous cellular processes ranging from cell division, organ-
elle positioning, intracellular transport, to neuronal differentiation.
The MT-associated protein tau is the best known for its being essential
for the assembly and stabilization of MTs in the neuronal system
[1–3]. Thus, it is understandable that tau dysfunction is correlatedeimer's disease; BSA, bovine
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rights reserved.with a variety of neurodegenerative diseases including Alzheimer's dis-
ease (AD), front-temporal dementia with parkinsonism linked to chro-
mosome (FTDP-17) and Pick's disease and that these diseases are
referred to as ‘tauopathies’ [4–6].
Expression of tau in the neuronal system is extraordinarily com-
plicated: Multiple tau isoforms are generated from a single gene
through alternative mRNA splicing in a developmental stage- and
cell type-speciﬁc manner [7]. In human adult brain tau, exons 1, 4,
5, 7, 9, 11, 12 and 13 are constitutive and exons 2, 3, and 10 are alter-
natively spliced [7,8]. Exons 4A, 6, and 8 appear not to be transcribed.
Exon 14 is transcribed, but not translated. In turn, matured human
brain tau primary transcript gives rise to six mRNA: (Δ6,8),
(Δ6,8,10), (Δ3,6,8), (Δ3,6,8,10), (Δ2,3,6,8), and (Δ2,3,6,8,10). These
tau isoforms contain repetitive regions serving as MT-binding sites
in a domain encoded by exons 9–12. Tau isoforms resulting from
encoding exon 10 have four repeat regions, whereas those lacking
encoding exon 10 have three repeat regions [5–10]. Various factors
such as localization of abnormal tau affect the development of neuro-
degenerative diseases. Here we emphasize that the splicing also
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all six isoforms of brain tau have been found in the neuroﬁbrillary
tangle of paired helical ﬁlaments (PHFs), a hallmark of AD [11,12].
Inclusion bodies in FTDP-17 contain only tau isoforms with four
MT-binding regions [13], whereas inclusion bodies in Pick's disease
are entirely made from tau isoforms with three MT-binding regions
[14,15].
Regulation of tau is also highly complicated: Tau is tightly regulat-
ed by phosphorylation [2,10,16]. Remarkably, phosphorylation can
occur at 30–40 different sites in tau [17–20]. Normal human brain
tau contains 2–3 moles of phosphate per mole of protein, which ap-
pears to be optimal for its interaction with tubulin and promotion
of MT assembly [21]. However, the level of tau phosphorylation in
AD brain is 3- to 4 times higher than that in normal brain [22,23],
and, to date, ~20 phosphorylation sites have been identiﬁed in tau
associated with PHFs [17,24]. Two models have been proposed
for the mechanism leading to neurodegenerative diseases by hyper-
phosphorylation: “toxicity” and “erroneous regulation” [25]. In the
former model, hyperphosphorylation leads to formation and accumu-
lation of toxic tau ﬁbers and these ﬁbers cause cell death by virtue of
their cytotoxicity [26,27]. In the latter model, hyperphosphorylation
converts normal tau to an inhibitory molecule that sequesters normal
MT-associated proteins from MTs and, in turn, leads to cell death
[25,28]. The following enzymes have been identiﬁed as major tau pro-
tein kinases: cAMP-dependent protein kinase (EC 2.7.11.11), Ca2+/
calmodulin-dependent protein kinase II (EC 2.7.11.17), cyclin-
dependent protein kinase 5 (Cdk5) (EC 2.7.11.22), stress-activated
protein kinases (EC 2.7.11.24) and glycogen-synthase kinase-3β (EC
2.7.11.26).
The retina, a part of the visual system, contains both tau [29,30]
and protein kinases responsible for brain tau hyperphosphorylation
[31,32]. Recent studies suggest that abnormal tau may play a role in
some retinal degenerative diseases [33–41]. A common viewpoint in
these studies is that these retinal diseases may share, at least in
part, the mechanism of tau-related brain diseases and that informa-
tion about these brain diseases may be applied to explain these reti-
nal diseases. This view may use to collectively analyze these retinal
diseases. However, the basis of this view may not be strong, i.e., to
our understanding, tau in retina (or in individual retinal cells) has
not been thoroughly characterized, and the characteristic of retinal
tau has not been fully compared with that of brain tau. In addition,
the information about retinal tau is based on the tau derived from
the whole retina that is composed of various cells, and thus some
characteristics may be blurred.
This study collectively examines the common view of these previ-
ous studies by characterizing tau in bovine retinal photoreceptor rod
outer segments (ROS), i.e., in a single type of retinal cells, and by com-
paring its characteristics with that of bovine brain tau. We ask three
basic questions in the characterization: (1) whether ROS contains
tau isoforms identical to those in brain, (2) whether ROS tau
shows the phosphorylation pattern similar to that of brain tau, and
(3) whether ROS tau interacts with MTs in a manner similar to that
of the association of brain tau with MTs. We show that ROS tau is
not necessarily similar to brain tau and that the difference from
brain tau as well as the similarity with brain tau should be considered
in the investigation of tau-related degenerative diseases, if any, in
retina.
2. Materials and methods
2.1. Materials
Dark-adapted frozen bovine retinaswere obtained from J. A. Lawson
Co. (Lincoln NE). Fresh retinas were isolated from dark-adapted calf
eyes obtained from a local slaughterhouse. Bovine brain was obtained
from a local slaughterhouse. Alkaline phosphatase (AP) (EC 3.1.3.1)from Escherichia coli was purchased from Sigma (St. Louis, MO).
Immobilon-PSQ transfer membrane was from Millipore (Billerica,
MA). Ultra Super Signal chemiluminescent substrate and peroxidase-
labeled anti-rabbit IgG and anti-mouse IgGwere from Pierce (Rockford,
IL). Ampholyte (3–10, 40%), Ampholyte (4–6, 40%), Ampholyte (5–8,
40%), Ampholyte (8–10, 20%) and IPG-strips were obtained from
Bio-Rad (Hercules, CA). All other chemicals were purchased from
Sigma unless otherwise indicated.
2.2. Antibodies
Rabbit anti-human tau antibody (A0024, 1:5000), obtained from
Dako (Carpinteria, CA), was regularly used. Phosphorylation site-
speciﬁc antibodies, PS262 (44750G), PS396 (44752G) and PS404
(44758G), and their blocking peptides were from Biosource (Camarillo,
CA). Anti-α-tubulin monoclonal antibody (T5168, 1:5000) and anti-β-
tubulin monoclonal antibody (T5293, 1:200) were from Sigma.
2.3. Preparation of bovine brain and ROS samples
This study used bovine preparations unless otherwise indicated.
The reasons for the use of bovine preparations are described in
Discussion section. Protein concentration was assayed with bovine
serum albumin (BSA) as a standard [42]. Bovine brain (5 g protein)
was suspended in 5 volumes of a 1.5 times-concentrated buffer A
(10 mM HEPES, pH 8.2, 1 mM dithiothreitol (DTT), 5 mM MgCl2,
5 μM leupeptin, 5 μM pepstatin A, 0.1 mM phenylmethylsulfonyl
ﬂuoride (PMSF), 9.5 TIU/l aprotinin and 1 μM E-64) and homoge-
nized by using a 18 G needle (×7) and then a 23 G needle (×7).
The mixture was divided into 200 μl aliquots per tube and kept at
−80 °C. Bovine ROS was obtained from dark-adapted frozen retinas
[43] or fresh retinas from dark-adapted calf eyes [44]. After homoge-
nizing in 400 μl of buffer A, ROS (1.0 mg protein) was centrifuged
(350,000 ×g, 20 min, 4 °C) to obtain membrane and soluble fractions.
The soluble fraction was again centrifuged to remove contamination
by membranes. The precipitation was suspended in 400 μl of buffer
A and used as the membrane fraction.
2.4. Identiﬁcation of tau isoforms
Bovine tau isoforms are generated from a single gene, and their
molecular weights (MWs) are distinctive. Therefore, ROS tau proteins
having identical MWs to those of brain tau isoforms are regarded as
ROS tau isoforms containing the same exon combination as those in
brain tau. Here SDS-PAGE was used to obtain these MWs, i.e., their ap-
parent MWswere compared. The SDS-PAGE systemwe used has been
proven to be excellent for protein isolation [45].
Brain (1.0 mg protein) and ROS (1.0 mg protein) were separately
suspended in 400 μl of buffer A. Each preparation was divided into two
tubes (150 μl), and to each tube, 10 μl of an AP solution (32 unit/ml
AP, 0.32% NaN3 and 1.6 mM ZnCl2) or 10 μl of a phosphatase-inhibitor
solution (160 mM NaF, 1.6 μM okadaic acid, 0.32% NaN3 and 1.6 mM
ZnCl2) was added, and these mixtures were incubated for 18 h at
33 °C. After adjusting the volume of ROS and brain mixtures by adding
buffer A to 300 μl and 1200 μl, respectively, 10, 20, 30 and 40 μl of
these samples were applied to a 8–16% acrylamide-gradient gel
(12 × 17 cm). Proteins were then blotted to a nylon membrane and
tau was detected with a rabbit anti-human tau antibody. These proteins
are named tau-antibody-sensitive proteins hereafter.
Antibody signal intensities were used for the estimation of tau
concentration in ROS, because this allows the concentration to be
measured rapidly and simultaneously when multiple tau isoforms
are present. However, a linear relationship between the signal in-
tensity and the protein level is difﬁcult to establish. To reduce this
ambiguity, four samples containing different protein amounts were
applied to a gel and their signal intensities were compared. All
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lar. The data shown are representative of these experiments.
2.5. Determination of the phosphorylation status of tau isoforms in ROS
After treatment with or without AP, proteins were separated by
regular SDS-PAGE or two-dimensional electrophoresis. The phos-
phorylation status was then estimated based on the changes in
their migration proﬁles caused by the AP treatment. (1) Regular
SDS-PAGE. After isolation, tau proteins were detected with an
anti-human tau antibody, as described above. (2) Two-dimensional
electrophoresis. ROS (1–5 mg protein) was homogenized in 200 μl
of buffer A and centrifuged (350,000 ×g, 20 min, 4 °C). The soluble
fraction was again centrifuged to remove contamination by mem-
branes. The membrane fraction was washed with 200 μl of buffer B
(10 mM MOPS, pH 7.5, 1 mM DTT, 5 mM MgCl2, 5 μM leupeptin,
5 μM pepstatin A, 0.1 mM PMSF and 200 mM NaCl) (×2). Then its
volume was adjusted to 200 μl by adding buffer A. These preparations
were divided into two tubes (70 μl), and 5 μl of the AP solution or 5 μl
of the phosphatase-inhibitor solution was added to each tube.
These mixtures were incubated for 18 h at 33 °C. These samples
were then subjected to non-equilibrium pH-gradient electrophoresis.
In brief, these samples were mixed with 305 μl of 1.26 time-
concentrated rehydration buffer {7 M urea, 2 M Thio-urea, 4%
CAHPS, 50 mM DTT, 0.1% Ampholyte (3–10, 40%), 0.1% Ampholyte
(4–6, 40%), 0.1% Ampholyte (5–8, 40%), 0.1% Ampholyte (8–10,
20%), and 0.001% bromophenol blue) and applied to IPG-strip
(11 cm, pH 3–10), and active rehydration was performed in an IEF
Cell (Bio-Rad) as recommended by the manufacturer. The proteins
were focused at 3400 V for 36,000 Vh. The strips were equilibrated
under reducing conditions (6 M urea, 20% glycerol, 2% SDS, 2% DTT,
and 0.375 M Tris, pH 8.8) for 15 min and then alkylated for 15 min
(6 M urea, 20% glycerol, 2% SDS, 2.5% iodoacetamide, and 0.375 M
Tris, pH 8.8). Each strip was then transferred to a vertical SDS-PAGE
with an 8–16% acrylamide-gradient gel (12 × 17 cm).
2.6. Detection of tau and tubulins by immunogold electron microscopy
Rat (Wister rat) and frog (Rana catesbiana) retinas isolated freshly
were used to avoid possible postmortem changes in bovine retina.
Western blotting using the tau antibody sensitive to bovine tau
showed that tau-antibody-sensitive proteins in rat and frog retinas
were similar, if not identical, to those in bovine retinas although the
level of frog proteins appeared to be slightly less. These animal exper-
iments were approved by the Regulatory Committee of Animal Exper-
iments in Nagoya University and conformed to the guidelines
outlined in the National Instituted of Health Guide for Care and Use
of Laboratory Animals.
Rat retinaswere ﬁxedwith 1% glutaraldehyde and 4% paraformalde-
hyde in 100 mM HEPES (pH 7.4). Frog retinas were also treated in the
same way. These retinas were dehydrated through an ascending series
of ethanol up to 95%, and then soaked in a mixture of Lowicryl K4M
resin (Polysciences Inc. Warrington, PA) and 95% ethanol for 1 h. Spec-
imens were transferred into fresh Lowicryl K4M resin and keep in
refrigerator overnight. Retinas were again transferred into gelatin
capsules ﬁlled with fresh Lowicryl K4M resin and polymerized under
UV light for 3 days. Thin sections were obtained in a conventional
way and mounted on 200-nickel-grid coated with formval. Protein la-
beling was then carried out as previously described [46]. In brief, the
sections blocked with 4% BSA for 10 min were incubated with
anti-tubulin α or β antibodies or anti-tau antibody (ﬁnal concentration
0.2 mg/ml) in PBS containing 1% BSA for 2 h, rinsed 7 times with PBS,
and then incubated on 10 or 15 nm gold-conjugated goat anti-rabbit
or -mouse IgG (Amersham, Uppsala, Sweden) at a dilution of 1:30 in
1% BSA/TBS for 1 h. After being washed 8 times with PBS (1 min
each), grids were post-ﬁxed in 2% glutaraldehyde for 20 min andwashed well with distilled water. Control sections were processed in
the same way, except that preimmune serum was substituted for the
anti-tubulin and anti-tau protein antibodies. As another control, an ex-
cess amount of peptide antigen (2 mg/ml: 10 times higher than the an-
tibody concentration) was added during primary antibody incubation.
Two controls showed the same imageswithout speciﬁc labeling. All sec-
tions were stained with 5% uranyl acetate in distilled water prior to
observation.
3. Results
3.1. Bovine brain tau
This study characterizes bovine ROS tau based on information
about bovine brain tau. Bovine brain tau isoforms, like human brain
tau isoforms, are generated from a single gene through alternative
mRNA splicing [7,47]: Exons 1, 2, 4, 5, 7, 9, 11, 12 and 13 are found
in all tau isoforms, while exons 3, 8 and 10 are alternatively spliced.
Isoforms having domains encoded by exons 6 and 14 were reported;
however, levels of these isoforms were negligible [47]. Isoforms con-
taining the domain encoded by exon 8 were also present; but their
total level was less than 2% of the total tau [48]. Therefore, it has
been concluded that bovine brain tau has four major isoforms
(Δ6,8), (Δ6,8,10), (Δ3,6,8) and (Δ3,6,8,10) (Fig. 1). These four iso-
forms were actually obtained from bovine brain [8,49]. Importantly,
these isoforms are also present in human brain [4,10]. In addition, all
tau domains, especially domains encoded by exons 9–13, are homolo-
gous in these two species (Fig. 1). It is thus expected that the primary
property of bovine brain tau is quite similar to that of human brain tau.
As an example for the structure similarity, anti-human tau antibodies
recognize bovine brain tau isoforms, as shown previously [7,8] and
below.
Based on their migration proﬁles published previously [8], we es-
timated the apparent MWs of major bovine brain tau isoforms
(Fig. 1). Three points should be noted. First, these apparent MWs
are much larger than their calculated MWs, i.e., the MWs predicted
from their cDNA sequences. This characteristic is also observed in
human brain tau and is believed to be due to its hydrophilicity
[10,50]. Second, the apparent MW of isoform (Δ6,8,10) is larger
than that of isoform (Δ3,6,8) although the calculated MW of the for-
mer isoform is smaller than that of the latter isoform (Fig. 1). This in-
consistency is also observed in human brain tau isoforms [8,51].
These observations imply that the domain encoded by exon 3 and/
or 10 is crucial for the structure of tau protein. Third, these apparent
MWs were obtained by SDS-PAGE. The SDS-PAGE conditions may
not be identical in all experiments, and thus the apparent MW
obtained may vary. This study compared apparent MWs of ROS tau
isoforms with those of brain isoforms for identiﬁcation of ROS isoforms.
We compare these MWs only when these MWs are obtained under ex-
actly the same conditions for SDS-PAGE.
3.2. Identiﬁcation of tau isoforms present in bovine ROS
After separation by SDS-PAGE, the migration proﬁle of ROS tau
was compared with that of bovine brain tau (Fig. 2). We found that
ROS contained tau-antibody-sensitive proteins of which apparent
MWs were identical to those of brain major tau isoforms, i.e., ROS
contained isoforms (Δ6,8), (Δ6,8,10), (Δ3,6,8) and (Δ3,6,8,10). We
also found that ROS had seven additional tau-antibody-sensitive pro-
teins (⋆1–⋆7). Proteins (⋆1), (⋆2), (⋆6) and (⋆7) do not have apparent
MWs identical to any of brain proteins; but proteins (⋆3–⋆5) appear
to have apparent MWs identical to those of brain proteins (⋆b–⋆d),
respectively (Fig. 2B). Among them, levels of isoforms (Δ6,8,10),
(Δ3,6,8) and (Δ3,6,8,10) and tau-antibody-sensitive protein (⋆5) and
(⋆7) were evidently large in ROS. Their antibody signal intensities indi-
cates that the order of these levels was: isoform (Δ3,6,8,10) ≥ isoform
Exon No
Polypeptide
MW (kDa)
Homology with
human tau (%)
1 2 7 3 6 54 9 10 11 12 13 8 
46 9693 8686 8884 100 100100 100
3.8 2.72.9 2.2 3.32.0 9.04.1 3.0 4.0 7.5
A 
B 
Calculated MW (kDa)
6,8
6,8,10 1 2 7 3 54 9 11 12 13 
1 2 7 3 54 9 10 11 12 13 44.5
41.2 59.7
63.3
3,6,8 
3,6,8,10
Apparent MW (kDa)
1 2 7 54 9 11 12 13 
1 2 7 54 9 10 11 12 13 41.8
38.5 53.6
57.2
Tau
isoforms
Ser269 Ser403 Ser411 
Fig. 1. Schematic representation of bovine tau exons and major tau isoforms exited in bovine brain. (A) Exons. Numbers below each exon indicate the MW of the domain encoded
by the exon and the level of its homology with that of human brain tau. These MWswere calculated based on their amino acid sequences. Neither the MW nor the level of homology
of polypeptides encoded by exons 6 and 8 is shown because these exons are not transcribed in human brain. Ser269, Ser403 and Ser411 are the phosphorylation sites we focus on in
this study. The relative size of these exons is not drawn to scale. (B) Four major tau isoforms in brain. Their calculated MWs were obtained based on their amino acid sequences.
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ingly, the level of isoform (Δ6,8), one of major isoforms in brain, ap-
pears to be negligible in ROS, and protein (⋆5), one of major isoforms
in ROS, seems to be negligible in brain. The result also indicates that ap-
parent MWs of ROS tau isoforms, similar to brain tau isoforms, were
much higher than their calculated MWs.
Treatment with AP entirely dephosphorylates ROS tau isoforms,
as shown later (Fig. 3). This AP treatment categorizes these ROS tau-
antibody-sensitive proteins into four groups: (1) Proteins detected
clearly after the AP-treatment. Proteins (⋆1), (Δ6,8) and (⋆2) belong
to this group (Fig. 2A). This phenomenonwas also seen inmembranous
tau-antibody-sensitive proteins (Fig. 5A). Interestingly, this phenome-
non was observed only with proteins having relatively higher apparent
MWs (Figs. 2A and 5A), and clear detection often accompanied an
increase in the amount of these proteins (Fig. 5A). The simplest expla-
nation of these observations is that only these proteins had been phos-
phorylated and thus would diffuse on the SDS-gel and that these
proteins, when dephosphorylated, would be concentrated into their
own protein-bands and thus appeared to increase their amounts. Alter-
natively, if all ormost of tau-antibody-sensitive proteins had been phos-
phorylated, the phosphorylation level of these proteins would bemuch
higher than that of other proteins. Importantly, bovine brain proteins
did not show the same phenomenon (Fig. 1A). (2) Proteins reducing
their quantities with the AP treatment. Isoform (Δ6,8,10) belongs to
this group (Fig. 2A). This phenomenon was also observed in mem-
branes (Fig. 5A). The simplest explanation of the observation is that iso-
form (Δ6,8,10) had been phosphorylated and that dephosphorylation
would change its conformation followed by increase in its sensitivity
to proteolytic digestion. The proteolytic enzyme should be speciﬁc to
the isoform because isoforms (Δ3,6,8) and (Δ3,6,8,10) did not reduce
their quantities under the same conditions. In brain, tau-antibody-
sensitive protein (⋆a) and isoform (Δ6,8) appeared to show this phe-
nomenon (Fig. 2A). (3) Proteins unaffected by the AP treatment.
Isoforms (Δ3,6,8) and (Δ3,6,8,10) and tau-antibody-sensitive protein
(⋆5) belong to this group. These proteins may not be phosphorylatedor if phosphorylated, their conformations may not be affected by de-
phosphorylation. In brain, isoforms (Δ6,8,10), (Δ3,6,8) and (Δ3,6,8,10)
belong to this group. (4) Proteins increasing their quantities with the
AP-treatment. Tau-antibody-sensitive protein (⋆7) may belong to this
group (Figs. 2A and 5A). Whenever protein (⋆7) was clearly detected,
the level of isoform (Δ6,8,10) was always reduced (Figs. 2A and 5A),
suggesting that protein (⋆7) may be a digested product of isoform
(Δ6,8,10). We also note that protein (⋆7) was sometimes vaguely
detected, as shown later (Fig. 4). The simplest explanation of this obser-
vation is that the proteolytic digestion of isoform (Δ6,8,10) might be
somehow suppressed, and thus protein (⋆7) might not be produced.
All together, we speculate that protein (⋆7) may be an artifact and not
be a tau-antibody-sensitive protein present originally in ROS. In brain,
tau-antibody-sensitive protein (⋆a) and isoform (Δ6,8) appeared to re-
duce their quantities with AP treatment. However, the protein corre-
sponding to protein (⋆7) was not detected. These brain proteins might
have been further digested and then diffused.
Based on observations described above, we conclude as follows:
(1) Bovine ROS contains at least four tau isoforms (Δ6,8,10),
(Δ3,6,8), (Δ3,6,8,10) and (⋆5). This implies that tau isoforms may
play a variety of roles in ROS. (2) Isoform (⋆5) is present in ROS but
may not be present or be negligible in brain. The protein may be a
ROS-speciﬁc (or retina-speciﬁc). In addition, the level of isoform
(Δ6,8), one of major isoforms in brain, appears to be negligible in
ROS. These observations strongly suggest that combination of ROS
isoforms is different from that of brain isoforms, i.e., functions of
ROS tau may not be comparable to those of brain tau. (3) ROS tau
isoforms, at least some, are phosphorylated.
Apparent MWs of bovine brain tau isoforms we obtained (Fig. 2B)
were different from those previously reported (Fig. 1). This difference
may be due to the different conditions for SDS-PAGE as described
above. We also note that the migration proﬁle of ROS tau-antibody-
sensitive proteins was not changed even after long incubation (for
18 h at 33 °C), suggesting that these proteins might not be spontane-
ously dephosphorylated under our conditions. Various phosphatase
AB
Fig. 2. Detection of tau isoforms existed in bovine ROS. (A) Comparison of running proﬁles
of bovine ROS tau isoforms with those of bovine brain isoforms. Preparations of ROS and
brain (1 mg) were suspended in 400 μl of buffer A. After being divided into two tubes
(150 μl), each preparation was treated with or without AP. After diluting with the same
buffer to 300 and 1200 μl, respectively, these preparations (10, 20, 30 and 40 μl) were ap-
plied to a SDS-gel and tau-antibody-sensitive proteins were detected. (B) In-depth com-
parison of the running proﬁle of ROS tau-antibody-sensitive proteins with that of brain
isoforms. A running proﬁle of ROS proteins (lane a in A) is compared with that of brain
proteins (lane b in A). Four tau isoforms were identiﬁed to be identical to bovine brain
isoforms. Unknown are exons encoded following isoforms (*1– *7 in ROS, and *a–*g in
brain).
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Fig. 3. Running proﬁle of tau-antibody-sensitive proteins present in ROS membranes in
the two-dimensional electrophoresis. (A) Use of a relatively large amount of membranes.
After homogenization of a ROS preparation (1 mg) in 400 μl of buffer A, membranous
fractionswere obtained. Themembrane fractionwas treatedwith orwithout AP, and pro-
teinswere separated by a pH gradient and then by theirMWs. (B) Use of a relatively small
amount ofmembranes. ROSmembranes (100 μg)were subjected to the two-dimensional
electrophoresis. Exposure time of the tau/antibody-attached nylon membrane to ﬁlms
was two times longer than that in (A). A part containing the tau-antibody-sensitive pro-
teins belonged to group a is enlarged. Two isoforms (⋆1) and (⋆2) are identiﬁed as
isoforms (Δ3,6,8) and (Δ3,6,8,10), respectively.
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natively, their migration proﬁles would be unchanged even if some of
them were spontaneously dephosphorylated. We further note that
migration proﬁles of these ROS proteins obtained freshly from calf
eyes were similar, if not identical, to those from frozen retina, imply-
ing that biochemical characteristics of these proteins such as their
phosphorylation status may be unchanged or their changes may be
negligible during storage of these retinas. Similarly, biochemical char-
acteristics of brain tau might not be affected by postmortem changes
although we cannot deny the possibility.
3.3. Analysis of ROS tau isoforms with two-dimensional electrophoresis
After treating with or without AP, tau isoforms in ROS membranes
were separated ﬁrst by isoelectric focusing and then by vertical
SDS-PAGE (Fig. 3A). We found that tau-antibody-sensitive proteins
present in ROS membranes were separated into two groups; group
a: proteins scattered in a pH range ~6.7–8.3, and group b: proteinsconcentrated in a narrow range above pH 8.3. We also found that pro-
teins in group a were dominant before the AP treatment, whereas
only proteins belonged to group b were present after the AP treat-
ment. These observations strongly suggest that proteins in group a
were phosphorylated, while proteins in group b were completely
dephosphorylated. We note that spontaneous dephosphorylation on
proteins in group a cannot be denied during the long incubation, as
discussed above. However, the result (Fig. 3A) clearly indicates that
tau-antibody-sensitive proteins are still phosphorylated even after
the possible spontaneous dephosphorylation. The soluble fraction
was also examined; however, the result was not clear due to a very
low content of tau proteins. This low content is due to their tight
binding to membranes. This characteristic will be described later
(Fig. 5 and Supplementary data).
Proteins in group a were clearly separated from proteins in group
b (Fig. 3A). This observation, together with the observation that al-
most all proteins belonged to group a before the AP treatment
(Fig. 3A, -AP), strongly suggests that all tau-antibody-sensitive pro-
teins present in membranes were phosphorylated. Almost all these
proteins are membrane-bound, as described above. We therefore
conclude that all ROS tau isoforms are phosphorylated. The phosphor-
ylation status of isoforms (Δ3,6,8), (Δ3,6,8,10) and (⋆5) was not clear
in the result depicted in Fig. 2. However, this study clearly indicates
that these isoforms are also phosphorylated. Phosphatase 2A (EC
3.1.3.16), a major protein phosphatase for dephosphorylation of
hyperphosphorylated tau isoforms in human brain [4,10,52], is
present in ROS [53,54]. However, the observation (Fig. 3A) suggests
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Fig. 4. Some of ROS tau isoforms contain phosphorylated sites identical to those in tau isoforms associated with PHFs. Phosphorylation-site-speciﬁc antibodies against human tau,
PS262 (A), PS396 (B) and PS404 (C), were used to identify bovine isoforms having these phosphorylated sites, Ser269, Ser403 and Ser411, respectively. Membranes were obtained
from a ROS preparation (850 μg) and suspended in 640 μl of buffer A. The suspension, 10 and 50 μg protein, were subjected to SDS-PAGE. Then proteins were blotted to an
Immobilon-P nylon. ROS tau isoforms in each lane were then detected: lane 1, 10 μg protein and DAKO polyclonal anti-human tau antibody; lane 2, 50 μg protein and a
phosphorylation-site-speciﬁc antibody; and lane 3, 50 μg protein and a phosphorylation-site-speciﬁc antibody pretreated with an antigen-peptide. Pretreatment with
antigen-peptides was carried out as recommended by the manufacture. The following tau antibody-sensitive proteins were identiﬁed in lane 1: a, isoform (Δ6,8,10); b, isoform
(Δ3,6,8); c, isoform (Δ3,6,8,10); d, isoform (⋆5) and e, tau-antibody-sensitive protein (⋆7). x is an unidentiﬁed protein.
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might deactivate the enzyme. ROS used in this study was obtained
from fresh retina of ordinary calf eyes or frozen bovine retina, i.e.,
the great majority of ROS was obtained from normal retinas. Thus, it
is concluded that all tau isoforms present in ROS are phosphorylated
under the normal conditions.
The precise migration proﬁle of tau-antibody-sensitive proteins in
group a was obtained by using a small amount of ROS membranes
(Fig. 3B). In this case, two tau isoforms (⋆1) and (⋆2), based on
their apparent MWs and quantities, were identiﬁed as isoforms
(Δ3,6,8) and (Δ3,6,8,10), respectively. The migration proﬁle showed
that these isoforms lined up as if they were scattered on two parallel
curves extended to points with a lower apparent MW and with a
higher apparent isoelectric point (pI). A similar proﬁle was also
obtained when a large amount of ROS membranes was used, although
isoforms were not clearly separated due to the overload of proteins
(Fig. 3A, -AP). The simplest explanation of the proﬁle is that each iso-
form chain consists of the same isoform, that the isoform with the
lowest apparent pI is modiﬁed with the highest numbers of phos-
phate and that the phosphate number is reduced stepwise as shifting
to the next spot with a higher apparent pI (and a lower apparent
MW), but the isoform having the highest apparent pI still contains a
phosphate molecule(s). Thus, it is likely that tau isoform, even the iso-
form having the same structure, is modiﬁed with a variable number of
phosphate molecules in ROS. In addition, the tau antibody-signal inten-
sities of these spots were not even (Fig. 3B), suggesting that amounts of
tau isoforms phosphorylated differently also varied. How complicatedly
ROS tau is phosphorylated!
3.4. ROS tau isoforms, at least some, were phosphorylated at the same
sites as phosphorylated sites in tau isoforms associated with PHFs
Using phosphorylation site-speciﬁc antibodieswe examinedwheth-
er phosphorylated sites in ROS tau isoforms were identical to those in
isoforms found in PHFs (Fig. 4). We chose three sites: Ser262, Ser396
and Ser404 in human tau. Phosphorylation at Ser262 attenuates the
ability of tau to bind MTs [4,10,55–57]. Ser262 is also among the phos-
phorylation sites that convert tau to an inhibitory molecule thatsequesters normalMT-associated proteins fromMTs [25,28]. Phosphor-
ylation at Ser396 and Ser404 promotes self-aggregation of tau into ﬁla-
ments [4,10,55–57].
Antibodies PS262, PS396 and PS404 recognize human tau isoforms
phosphorylated at Ser262, Ser396, and Ser404, respectively. We ex-
pect that these antibodies also recognize bovine tau isoforms phos-
phorylated at sites corresponding to these sites in human tau, i.e.,
Ser269, Ser403 and Ser411, for the following reasons: S269 in bovine
tau is located in the peptide encoded by exon 9, and the bovine pep-
tide is 96% homologous to the human peptide (Fig. 1). Moreover, the
sequences of the Ser269-containing portion, which is composed of 26
amino acids (P256 to K281 in bovine tau, and P249 to K274 in human
tau), are identical in these two species. Both Ser403 and Ser411 are
located in the domain encoded by exon 13, and the domain is identi-
cal in these two species (Fig. 1).
Our results (Fig. 4) showed that phosphorylated Ser269 was
detected in isoform (⋆5), that phosphorylated Ser403 was observed
in isoforms (Δ3,6,8) and (Δ3,6,8,10), and that phosphorylated
Ser411 was detected in isoforms (Δ3,6,8) and (Δ3,6,8,10). Phosphor-
ylated Ser403 was also seen in tau isoform x, a tau isoform with an
unknown exon combination. Phosphorylated Ser403 also appeared
to be present in isoform (Δ6,8,10); however, this identiﬁcation may
not be conclusive because of an imprecise separation of phosphory-
lated isoforms. Together, we conclude that at least some ROS tau
isoforms are phosphorylated at the same site(s) as phosphorylated
sites in tau isoforms associated with PHFs. It is unknown now wheth-
er these ROS tau isoforms express abnormal characteristics.
We note that these three phosphorylation sites are present in do-
mains encoded by exons 9 or 13 (Fig. 1) and that isoforms (Δ6,8,10),
(Δ3,6,8) and (Δ3,6,8,10) contain these domains. However, PS262
detected none of them (Fig. 4A), suggesting that Ser269 was not
phosphorylated in these isoforms. In addition, the PS396 signal inten-
sity of isoform (Δ3,6,8,10) was clearly less than that of isoform
(Δ3,6,8) although the PS404 signal intensity of isoform (Δ3,6,8,10)
appeared to be similar to that of isoform (Δ3,6,8). Moreover, PS404
did not recognize isoform (Δ6,8,10). These observations strongly sug-
gest that these isoforms are individually phosphorylated. It is possible
that conformation of these isoforms may be different from each other
Fig. 5. Solubility of ROS tau-antibody-sensitive proteins. (A) Tau-antibody-sensitive pro-
teins inmembrane and soluble fractions. Soluble andmembranous fractions were obtained
from ROS (1.0 mg). After adjusting volumes of these fractions to 400 μl by adding buffer A,
each fraction was divided into two portions (150 μl) and treated with or without AP. After
diluting with the same buffer to 300 μl, these preparations (10, 20, 30 and 40 μl) were
subjected to SDS-PAGE, and then proteins were detected using a tau-speciﬁc antibody.
(B) Tau-antibody-sensitive proteins in buffer A containing n-Dodecyl-β-D-maltoside. ROS
membranes (500 μg) were suspended in buffer A (200 μl) containing 1% n-Dodecyl-
β-D-maltoside and incubated for 1 h on ice. The mixture was centrifuged, and the precipi-
tate and supernatant were obtained. After adjusting the volume to 150 μl by adding the
same buffer, these samples (10, 20, 30 and 40 μl) were applied to a SDS-gel, and proteins
were tau detected. (C) Tau-antibody-sensitive proteins in buffer A containing Triton
X-100. ROSmembranes (500 μg) were suspended in buffer A (200 μl) containing 1% of Tri-
ton X-100, incubated and centrifuged, as described in (B). After adjusting the volume to
150 μl by adding the same buffer, these samples (50 μl) were applied to a SDS-gel and
tau isoforms were detected as described in (B). The tau-antibody-sensitive protein (✶)
was identiﬁed as protein (★7).
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We also note that several faint bandswere detectedwhen PS262 was
premixed with the antigen peptide (Fig. 4A). We also occasionally saw
similar faint bands even when the sample was pretreated with AP.
These faint bands were also observed when other phosphorylation-
site speciﬁc antibodies were used on AP-pretreated isoforms. These ob-
servations imply that these antibodies, at least some of them, may not
be highly speciﬁc. However, with antibodies we chose, protein bands
described here were consistently and clearly observed, and faint
bands, even if detected, were not located in the position identical to
that of these clear bands. Therefore, we conclude that these antibodieshave a relatively higher speciﬁcity to these phosphorylated tau isoforms
and are usable to identify them.We use this method because this meth-
od is convenient to identify rapidly and simultaneously an isoform
when multiple phosphorylated isoforms coexist. However, in future,
these phosphorylations should be further studied by using direct
methods.
3.5. Solubility of ROS tau isoforms
Human brain tau is enriched in four amino acids: proline, glycine,
lysine and serine. It has been reported that the high content of proline
and glycine forms a random-coil conformation and that tau adopts
this conformation that allows it to be a soluble protein [10,50]. Bovine
brain tau also shows the similar solubility [8,58]. Here we examine
the solubility of ROS tau isoforms by identifying isoforms in membra-
nous and soluble fractions (Fig. 5). We found that the membranous
fraction contained almost all tau-antibody-sensitive proteins, while
the soluble fraction had only a single type of the protein with a MW
~40 kDa. The ~40 kDa protein also appeared to be present in the
membrane fraction (Fig. 5A), suggesting that the ~40 kDa protein is
originally membrane-bound; however, the binding to membranes is
so weak that the protein is solubilized in part under our experimental
conditions. We also found that 10-20% of tau-antibody-sensitive
proteins in membranes were solubilized in a buffer containing 1%
n-Dodecyl-β-D-maltoside (Fig. 5B), while almost all these proteins
were solubilized in the same buffer containing 1% of Triton X-100
(Fig. 5C). All together, it is concluded that all ROS tau isoforms are
membrane-bound. This characteristic is clearly different from that of
brain tau. We believe that protein (✶) (Fig. 4B and C) was protein
(⋆7), but not the ~40 kDa protein, because these supernatants were
obtained from membranes washed extensively. The observation sug-
gests that binding of protein (⋆7) to membranes may be much sensi-
tive to detergents than the binding of other proteins. We have already
speculated that that protein (⋆7) may be an artifact and not be a
tau-antibody-sensitive protein present originally in ROS, as described
above.
We also investigated whether the binding of ROS tau-antibody-
sensitive proteins to membranes was affected by their phosphoryla-
tion (Supplementary data). After suspension in buffer A and treat-
ment with or without AP, ROS membranes were centrifuged to
obtain its supernatant and precipitate. We obtained the result identi-
cal to that shown in Fig. 5A, indicating that the AP-treatment altered
neither the amount nor the type of tau protein present in both frac-
tions. We also showed that this lack of the AP effect was not due to
the inactivity of AP (Supplementary data). We therefore conclude
that dephosphorylation does not affect the binding of these proteins
to membranes. The ~40 kDa protein appears to bind so weakly to
membranes, as described above; however, the protein belongs to
group a (Fig. 3A), indicating that the protein is phosphorylated.
These observations also support the conclusion.
3.6. ROS tau isoforms associate, besides MTs, with a cellular
component(s) in membranes
The photoreceptor contains a MT-based axoneme, which begins at
the basal body in the distal portion of the inner segment, passes
through the connecting cilium, and continues into the outer segment
for up to 80% of its length. MTs consist of protoﬁlaments, each made
up of α/β-tubulin dimmers [59,60]. Here, using immunogold electron
microscopy, we examined the localization of tau and MTs in retinal
photoreceptors (Fig. 6). When bovine preparations were used, the
shape of photoreceptor sometimes appeared to be slightly collapsed.
Therefore, retinas from rat and frog, but not bovine, were used to
avoid the possible postmortem changes in bovine retina.
We found, as expected, that tubulin αwas concentrated in the ax-
oneme in both rat and frog photoreceptors (Fig. 6Aa, Ba and Bb).
Fig. 6. Localization of tubulin α and tau in ROS. After isolation from rat and frog eyes
and blocking with 4% of BSA, thin sections of retina were incubated with mouse
anti-tubulin α antibody or a rabbit anti-tau antibody (ﬁnal concentration 0.2 mg/ml)
in PBS containing 1% BSA. These sections were rinsed with PBS, incubated on 10 or
15 nm gold-conjugated goat anti-mouse or anti-rabbit IgG and washed again with
PBS. Grids were ﬁxed in 2% glutaraldehyde and washed with distilled water. Then
these preparations were analyzed using an electron microscopy. Arrows indicate the
MT-based axoneme. Localization of tubulin β was also examined, but the result is not
shown. Scale bar, 400 nm.
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only with the axoneme (data not shown). However, the localization
of tau is clearly different from that of tubulin α/β. In the case of rat
photoreceptors, the tau signal was detected in the entire outer seg-
ment (Fig. 6Ab and Ac), while almost no signal was detected with
the axoneme (Fig. 6Ab). These results do not deny the possibility
that a small amount of tau binds to the axoneme in rat photorecep-
tors; however, these results clearly show that rat tau is mainly associ-
ated with a cellular component(s) other than the axoneme in ROS. In
the case of frog photoreceptors, the tau signal was also spread out
the entire outer segment (Fig. 6Bc). In this case, the axoneme could
not be identiﬁed, and thus, whether the frog tau was associated
with the axoneme could not be determined. However, the result
(Fig. 6Bc) strongly suggests that frog tau, like rat tau, is mostly asso-
ciated with a cellular component(s) other than the axoneme in
ROS. These observations, together with the observation showing
that ROS tau is membrane-bound (Fig. 5), imply that that the cellularcomponent is in membranes and that tau isoforms, besides the axo-
neme, bind to and stay with the component in ROS. The large size
of frog photoreceptor results in the reduction in the signal size of
both tubulin α and tau (Fig. 6B).4. Discussion
4.1. Why do we use bovine preparations?
First, we emphasize that bovine preparations appear to be appro-
priate to study the mechanism of human retinal diseases that may
share the mechanism of tau-mediated brain diseases. Bovine brain,
like human brain, tends to develop neuroﬁbrillary pathology [8,61],
and the primary property of bovine brain tau isoforms is similar to
that of human brain isoforms. These observations suggest that
tau-mediated diseases similar to those in human brain may also be
developed in bovine brain. In addition, bovine retina has a structure
similar to that of human retina. Thus, it can be further speculated
that, similar to the development of human brain diseases in human
retina, tau-mediated bovine brain diseases may also be developed in
bovine retina. Second, Cdk5, one of the protein kinases responsible
for the hyperphosphorylation of human brain tau, is present in bovine
retina including ROS [31,32]. Third, large quantities of bovine prepa-
rations are available. Bovine ROS is the only retinal portion that can
be obtained in large quantities and puriﬁed now. The purity of our
ROS preparation is at least more than 90% [43,44].
Followings are not limited to bovine preparations; however, they
are worthy of special mention: First, the tau interaction with MTs
can be easily estimated in retinal photoreceptor in situ because of lo-
calization of MTs in the axoneme in photoreceptors [59,60]. Second,
an enormous amount of information about ROS biochemistry, cell bi-
ology and physiology is available [62,63]. Finally, we emphasize that
ROS is a part of a retinal cell and that the study of ROS tau may reveal
the actual behavior of tau in a single type of retinal cells. Previous
studies about retinal tau were based on the tau derived from the
whole retina. Retina contains various types of cells. Thus, previous ob-
servations may blur cellular differences and not reﬂect the actual tau
behavior in a retinal cell.4.2. Is ROS tau composed of isoforms identical to those of brain tau?
We have shown that bovine ROS contains four isoforms as major
tau isoforms: (Δ6,8,10), (Δ3,6,8), (Δ3,6,8,10) and (⋆5) (Fig. 2). The
ﬁrst three isoforms are also found in brain (Fig. 1). We also found
that some of other ROS proteins showed migration proﬁles identical
to those of brain proteins although the amount of these proteins
was negligible. These observations support in part the view that
ROS tau is composed of isoforms identical of brain tau. However, we
also note that the level of isoform (Δ6,8), one of the major isoforms
in brain, is negligible in ROS and that ROS speciﬁcally contains iso-
form (⋆5) as a major tau isoform (Fig. 2). These indicate that the com-
bination of ROS tau isoforms (or retinal isoforms) is distinct from that
of brain tau. In addition, we emphasize that ROS (or a single type of
retinal cell) contains so many different tau isoforms. It is likely that
tau has various functions in ROS and that some of these functions
may be ROS-speciﬁc. These observations do not deny the possibility
that a certain type of cells in the brain may have a combination of
tau isoforms identical to those in ROS, and that these isoforms may
have functions similar to those of ROS isoforms. However, the protein
identical to isoform (⋆5) was negligible in the brain (Fig. 2), implying
that these cells may not be abundant in brain tissue. We therefore
conclude that ROS tau has a unique set of isoforms and that studying
of tau in both the entire retina and individual retinal cells is also cru-
cial to reveal the mechanism of tau-mediated retinal diseases.
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Normal human brain tau is phosphorylated with multiple phos-
phate molecules [21], implying that tau in bovine brain is also modi-
ﬁed with multiple phosphate molecules. Here we have suggested that
ROS tau isoforms are also modiﬁed with multiple phosphate mole-
cules and thus both brain and ROS tau may be regulated in a similar
manner. However, we emphasize that some ROS tau isoforms are
also phosphorylated in a speciﬁc manner. For example, ROS tau
isoforms, especially isoforms with high MWs, appear to be highly
phosphorylated (Figs. 2 and 5); however, brain isoforms are not
(Fig. 2). We also found that some ROS tau isoforms, even isoforms
obtained from normal retinas, were phosphorylated at the sites iden-
tical to those in PHFs, implying that phosphorylation of ROS tau ap-
pears to be speciﬁc to each isoform. (Fig. 4). These observations
suggest that some ROS tau isoforms are uniquely phosphorylated
and that these modiﬁcations may be required for normal function of
ROS tau. A simple application of the information about brain tau
phosphorylation may be inappropriate to explain phosphorylation
of tau in ROS (or in other individual retinal cells) and retina.
The phosphorylation status of ROS tau was estimated by the
change of its migration proﬁle by AP treatment and detection by
antibodies (Figs. 2, 3 and 5), because this procedure is suitable to
examine the phosphorylation status of all tau isoforms swiftly and
simultaneously under the same conditions. The speciﬁcity of the anti-
body regularly used, Dako rabbit anti-human tau antibody, was
conﬁrmed when tau localization in ROS was investigated (Fig. 6).
However, this procedure is not straightforward. In addition, phos-
phorylation site-speciﬁc antibodies may not be highly speciﬁc, as de-
scribed above. Thus, observations in experiments using antibodies
should also be further investigated by using direct methods such as
identiﬁcation of phosphorylated sites by proteomics, direct incorpo-
ration of [32P] into a speciﬁc tau isoform by a speciﬁc kinase(s), and
phosphorylation of site-speciﬁc tau mutant forms.
4.4. Does ROS tau bind to MTs in the same manner as brain tau does?
This question is crucial for tau. Thus, we started this study by ask-
ing a basic question: whether ROS tau is soluble or membrane-bound.
Bovine brain tau has been reported to be soluble [8,58]. However, bo-
vine ROS tau isoforms, even isoforms having the same structures
as those of brain isoforms, were membrane-bound (Figs. 3 and 5).
ROS tau might bind to and stay with MTs and thus appear to be
membrane-bound. However, tubulins α/β are concentrated in the ax-
oneme in photoreceptors, but tau is detected in the entire outer seg-
ment (Fig. 6). These results indicate that a great part of ROS tau
associates with a cellular component(s) other than MTs and that the
association results in the tight binding of ROS tau to membranes. De-
phosphorylation did not affect the solubility of ROS tau (Supplemen-
tary data), suggesting that phosphorylation is not primarily involved
in the tau association with the component. These observations do
not deny the possibility that a small amount of tau binds to the axo-
neme in photoreceptors; however, these observations clearly show
the uniqueness of ROS tau.
The apparent MWs of brain tau isoforms are much higher than
their calculated MWs (Figs. 1 and 2). This phenomenon has been
explained by their hydrophilicity [10,50]. ROS tau isoforms migrate
on the SDS-gel in the same manner as brain tau does, but ROS pro-
teins are membrane-bound (Fig. 5). We believe that the increase in
the apparent MW of ROS tau isoforms does not directly link to their
hydrophilicity, because the hydrophilicity is a property of a native
protein, but not a denatured protein, and this study obtained the ap-
parent MW of ROS tau after heating it in a SDS-containing sample
buffer. We believe that the denatured form of ROS tau has a tendency
to make a large micelle with a large number of SDS molecule under
the conditions that the stoichiometry of SDS bound to tau isoformsis relatively uniform. Therefore, apparent MWs of tau isoforms appear
to be substantially proportional to calculated MWs, but appear to be
much higher than their calculated MWs. We note that running pro-
ﬁles of ROS isoforms (Δ6,8,10) and (Δ3,6,8) did not follow their calcu-
lated MWs (Fig. 2). This inconsistency may also be due to a difference
in the size of micelles formed by these tau isoforms and SDS molecules,
and the domain encoded by exon 3 and/or 10may be crucial for binding
of SDS. Phosphate molecules attached to isoforms increase their appar-
ent MWs. However, the increase appear to be trivial because apparent
MWs of isoforms (Δ3,6,8), (Δ3,6,8,10) and (⋆5) appeared not to be al-
tered by the AP treatment (Figs. 2 and 5).
4.5. Is the cellular component crucial for ROS tau?
The cellular component is not identiﬁed in this study. However, it
is likely that the component affects both function and regulation of
ROS tau, because introduction of the component makes it much easier
to explain behavior of ROS tau. For example, ROS tau isoforms having
high apparent MWs, but not brain isoforms, were clearly detected
and separated only when they were pretreated with AP (Figs. 2
and 5). In this study, we interpret these observations as given
below: All ROS tau isoforms have been phosphorylated; however,
the phosphorylation level of isoforms with high apparent MWs is
much higher than that of other isoforms, and thus these isoforms dif-
fuse on a SDS-gel. In the case of brain isoform, these isoforms may not
be phosphorylated or if phosphorylated, their phosphorylation levels
may be much less that those of ROS isoforms, and thus, these brain
isoforms, whether phosphorylated or not phosphorylated, are con-
centrated on the SDS-gel. Two problems rise in the explanation:
(1) If only ROS tau isoforms are phosphorylated, our explanations
do not address why only ROS isoforms are phosphorylated, and
(2) if both ROS and brain tau isoforms are phosphorylated, our expla-
nations do not address why only ROS isoforms with high apparent
MWs show the phenomenon. However, with the cellular component,
these problems may be explained as follows: (a) ROS isoforms, but
not brain isoforms, make complexes with components and thus
only ROS isoforms are phosphorylated, and (b) ROS isoforms with
high MWs make complexes with speciﬁc components and thus the
phosphorylation level of these isoforms are much higher. We note
that explanation 1 is based on the fact that the phosphorylation pat-
tern of bovine brain tau is not clearly known. However, bovine
brain tau, like human brain tau, may be modiﬁed with multiple phos-
phate molecules, because structure of bovine brain tau is similar to
that of human tau (Fig. 1). Therefore, explanation 1 may be excluded.
We have also shown that AP treatment signiﬁcantly reduces the
amount of ROS isoform (Δ6,8,10) under the conditions that amounts
of isoforms (Δ3,6,8) and (Δ3,6,8,10) are not changed (Figs. 2A and
5A). We have explained the phenomenon as given below: Dephos-
phorylation of isoform (Δ6,8,10) would change its conformation,
and the change would increase its sensitivity to a proteinase(s). How-
ever, the AP treatment appears not to reduce the level of brain iso-
form (Δ6,8,10) (Fig. 2A). Thus, our explanation may not interpret
the difference between ROS tau and brain tau. However, with the cel-
lular component, the difference may be explained as follows: ROS iso-
form (Δ6,8,10), even after dephosphorylation, still keeps its complex
with the component (Supplementary data), and only the isoform as-
sociated with the component has a high sensitivity to a speciﬁc pro-
teinase. Together, these speculations may imply that the cellular
component has an important role(s) in regulation and function of
ROS tau. Identiﬁcation of the component and its characterization are
urgent.
4.6. Does ROS tau play a role in phototransduction?
Accumulating evidence suggests that tau, in addition to MTs, in-
teracts with various cellular components [4,10,64]. This study also
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other than MTs (Fig. 6), implying that ROS tau may have a function
other than the interaction with MTs. The function has not been yet
studied, because we have focused to examine collectively the current
view that tau-mediated retinal degenerative diseases can be
explained by using knowledge of tau-mediated diseases in brain,
and because the examination, we believe, is important for the prog-
ress in the study of tau-mediated retinal diseases. We only speculate,
as the function, that ROS tau may be involved in phototransduction,
because ROS is the site for phototransduction and the failure of
phototransduction causes retina degeneration. ROS tau may be associ-
ated with a protein(s) involved in phototransduction and the protein-
protein interaction may be disrupted by hyperphosphorylation of tau.
We have shown that Cdk5 phosphorylates Pγ, the inhibitory subunit
of cGMPphosphodiesterase (EC 3.1.4.35) (PDE),when rhodopsin is illu-
minated, i.e., when Pγ is complexed with GTP-Tα (GTP-bound form of
theα subunit of retinal G protein), and that PDE functionmay be altered
[31,65,66]. Interestingly, tau, like Pγ, has the sequence required for
phosphorylation by Cdk5 (S411-P412-R413 in bovine tau) and phos-
phorylated Ser411 was indeed found in tau isoforms (Δ3,6,8) and
(Δ3,6,8,10) (Fig. 4C). It is possible that Cdk5 may phosphorylate
Ser411 in these tau isoforms and that, with phosphorylation of other
sites, function of these tau isoforms in phototransduction may be
disrupted. GTP-Tα, similar to Pγ phosphorylation, may also be involved
in the phosphorylation of Ser411. If so, this model is clearly different
from the current model for phototransduction. We also expect that
the phosphorylation, if any, may be induced only after interaction of
isoforms (Δ3,6,8) and (Δ3,6,8,10) with a cellular component(s) speciﬁc
to these isoforms, because phosphorylated Ser411 is not found in iso-
form (Δ6,8,10) even though the isoform contains the site (Fig. 4C). In
any case, it is of great interest to evaluate the effect of proteins involved
in phototransduction on tau regulation or vice versa.4.7. Conclusion
We show that ROS has a unique combination of tau isoforms and
that regulation of these isoforms is not always comparable to those
in brain tau. We also suggest that ROS tau associates with, besides
the MT-based axoneme, other membranous component(s) and that
the interaction may be crucial for its function and regulation. Some
of these conclusions are based on indirect observations, and thus fur-
ther studies are needed. However, observations described here are
clear. Thus, we propose that knowledge about tau in the entire retina
and/or in individual retinal cells should also be clariﬁed and taken
into consideration in the study of tau-mediated retinal diseases.Acknowledgements
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